Research programme: Nuclear receptor modulators - Karo Pharma

Drug Profile

Research programme: Nuclear receptor modulators - Karo Pharma

Alternative Names: Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators; Nur77 modulators; NURR1 modulators

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio
  • Developer Karo Pharma AB
  • Class
  • Mechanism of Action Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 07 May 2013 Early research is ongoing in Sweden
  • 01 May 2012 Early research in Autoimmune disorders in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top